News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading
Citizens & Northern Corp (NASDAQ: CZNC) announced a $0.28 per share dividend, with an ex-dividend date of August 3, 2026. The company has a consistent dividend payment record since 1993, offering a 4.40% trailing and forward dividend yield. However, its dividend growth has been …
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).SOPHiA GENETICS Logo This multi-year collaboration agreement will advance …
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%Citizens has lowered its price target for MFA Financial Inc. (NYSE:MFA) to $11.00 from $11.50 due to increased credit stress, particularly in its transitional loan portfolios. Despite the reduced price target, Citizens maintained a Market Outperform rating. The company reported Q1 distributable EPS of …
Levi & Korsinsky is urging shareholders of Zenas BioPharma, Inc. (ZBIO) to act before the lead plaintiff deadline of June 16, 2025, in a lawsuit alleging that the company made false statements regarding its financial runway following its September 2024 IPO. The lawsuit claims …
This article analyzes Surrozen Inc. (NASDAQ: SRZN) focusing on its price action for tactical trading. It highlights mixed sentiment across different timeframes, with positive near-term sentiment potentially eroding a mid-term weak bias within a long-term strong context. The analysis also provides AI-generated institutional trading …
FCNCA Q2 Deep Dive: Balance Sheet Optimization and Relationship Banking Define 2026 Transition Regional banking company First Citizens BancShares (NASDAQGS:FCNC.A) announced better-than-expected revenue in Q2 CY2026, with sales up 1.5% year on year to $2.24 billion. Its non-GAAP profit of $57.09 per share was …
This article provides a revenue breakdown for Citizens Financial Group, Inc. Depositary Shares (CFG/PI), highlighting its top-performing segment and geographical contribution. Last year, the company generated $8.25 billion USD, with Consumer Banking being the largest contributor at $6.22 billion USD, and the United States …
AstraZeneca shares dropped significantly due to rumors of a potential mega-merger with Bristol Myers Squibb and a failed late-stage trial for its heart disease program, Wainua. Despite these setbacks, an investor is not selling, viewing the decline as a market overreaction rather than a …
Sharemaestro market context Price below Trend Line 52 weeks -1.4%Levi & Korsinsky, LLP has filed a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities during its September 2024 IPO. The lawsuit alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and …
This article provides a list of recent news headlines related to Roadzen, Inc. (RDZN), an insurance technology company. The news covers topics such as executive stock purchases, Q1 2025 earnings where Roadzen missed analyst estimates, reasons for stock movement (both gains and losses), and …
ZenaTech has filed an Early Warning Report due to its increased stake in Boardwalktech Software Corp. The company, along with its CEO, Dr. Shaun Passley, had their holdings diluted below 10% after a private placement by Boardwalktech. ZenaTech subsequently acquired additional Common Shares and …
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading
Citizens Financial Group, Inc. (SWB:1C5) reported a total revenue of €7.02 billion last year. The Consumer Banking segment was the highest-performing, generating €5.30 billion, slightly down from €5.50 billion the previous year. The majority of this revenue, €7.02 billion, came from operations within the …
Citizens Financial Group, Inc. announced the declaration of quarterly cash dividends on its preferred stock. The Board of Directors approved dividends for the Series B, C, D, and E preferred stocks, payable on August 21, 2026, to shareholders of record as of August 7, …
A recent report indicates that deal talks between AstraZeneca and Bristol-Myers Squibb are still ongoing. Following this news, Bristol-Myers Squibb's shares saw a slight increase, while AstraZeneca's shares experienced a minor decline. This update follows an earlier Financial Times report about potential acquisition discussions.
Morningstar reports on the potential megamerger between Bristol-Myers Squibb and AstraZeneca, noting that such large acquisitions are rare in biopharma. While the deal could combine complementary patent portfolios and pipeline assets, concerns exist regarding integration challenges and regulatory hurdles due to overlapping oncology focuses. …
Azenta, Inc. (AZTA) reported its Q3 revenue at $161.2 million, surpassing FactSet's estimate of $149.3 million. This financial news highlights a stronger-than-anticipated performance for the biotechnology and medical research company in its third fiscal quarter. The report also mentions other recent financial updates for …
Zentalis Pharmaceuticals announced that its Compensation Committee granted non-qualified stock options for 84,000 shares to two new employees. These grants were made under the 2022 Employment Inducement Incentive Award Plan, per Nasdaq Listing Rule 5635(c)(4), with an exercise price of $4.65 per share. The …
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company developing cancer, rare-disease and other medicines, plunged approximately 7.7% in Monday's U.S. regular-session trading as investors assessed reported merger discussions with Bristol Myers Squibb (NYSE:BMY), a U.S. biopharmaceutical company. A combination could …
Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion. …
PROVIDENCE, R.I., August 03, 2026--(BUSINESS WIRE)--Citizens Financial Group, Inc. (NYSE: CFG) announced that its board of directors has declared the following dividends on its preferred stock payable on October 6, 2026, to preferred shareholders of record at the close of business on September 21, …
Citizens Financial Group, Inc. (NYSE: CFG) announced that its board of directors has declared dividends on six series of its preferred stock. These dividends are payable on October 6, 2026, to shareholders of record as of September 21, 2026. The announcement includes specific cash …
Citizens & Northern Corp director Stephen M. Dorwart sold 2,278 shares of common stock on July 31, 2026, at a price of $25.372 per share. The transaction, described as an open market or private sale, resulted in Dorwart holding 4,270 indirect shares and 14,474 …
Citizens Financial Services, Inc. (Nasdaq: CZFS) reported unaudited consolidated financial results for the second quarter of 2026, showing significant increases in net income and net interest income compared to the previous year. Net income for the first six months of 2026 rose by 27.9% …
Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments
The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …
Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …
AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. Continue Reading
Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant. …
Search by ticker symbol or company name and select a result to open its chart.